链球菌的天然产品调解了与格拉姆阳性细菌病原体的物种间竞争
Ruth Y Isenberg1, Celine W Sackih1, Julia L E Willett1
1Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
口腔细菌Streptococcus mutans产生突变菌素,这种化合物可以杀死抗万科胺素的Enterococcus和其他阳性Gram细菌. 这一发现为对抗耐药性感染提供了新的策略.
科学领域:
- 微生物学 微生物学
- 药物发现 药物发现 药物发现
- 口腔健康 口腔健康
背景情况:
- 多微生物群落驱动细菌竞争,产生新的抗菌化合物.
- 口腔细菌,包括Streptococcus物种和Enterococcus faecalis,是口腔健康和疾病的关键参与者.
- 耐药性感染需要寻找新的治疗药物.
研究的目的:
- 为了研究口腔链球菌和Enterococcus faecalis之间的细菌间的竞争.
- 为了识别口腔细菌产生的抗菌化合物.
- 探索使用天然产品治疗耐药感染的策略.
主要方法:
- 共同培养实验以评估细菌相互作用.
- 抗菌化合物的识别和表征.
- 细菌膜透性的分析和依赖接触的杀死机制.
- 研究细菌竞争中涉及的毒性因素.
主要成果:
- 突变性菌株Streptococcus 抑制并杀死耐万科胺素的Enterococcus和其他阳性细菌.
- 由S. mutans产生的脂突变菌素中介抑制了格兰阳性细菌.
- 穆坦诺巴克增加了细胞的透性,杀死是接触依赖的.
- 需要Enterococcus faecalis凝酶 (GelE) 来恢复由突变菌素介导的杀死.
- 在S. mutans mutanobactin中,它可以抑制和消灭Enterococcus faecalis生物膜.
结论:
- 来自口腔细菌的天然产品,如S. mutans mutanobactin,在多微生物竞争中发挥着重要作用.
- 了解这些相互作用可以为开发抗药性细菌感染的新策略提供信息.
- 这项研究突出了口腔微生物群作为新抗菌药物潜在来源的潜力.
更多相关视频
09:08From a Natural Product to Its Biosynthetic Gene Cluster: A Demonstration Using Polyketomycin from Streptomyces diastatochromogenes Tü6028
Published on: January 13, 2017
07:43Coincubation Assay for Quantifying Competitive Interactions between Vibrio fischeri Isolates
Published on: July 22, 2019
相关概念视频
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Gene Regulation in Microbial Communities: Quorum Sensing
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Biological Methods for Microbial Control
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Microorganisms in Medicine and Therapeutics
